Nabriva Therapeutics PLC
Change company Symbol lookup
Select an option...
NBRV Nabriva Therapeutics PLC
HRB H & R Block Inc
GM General Motors Co
NDAQ Nasdaq Inc
DYYXF DB Commodity Double Long ETN
KIQ Kelso Technologies Inc
CBOE Cboe Global Markets Inc
PFE Pfizer Inc
DOW Dow Inc

*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements

Health Care : Pharmaceuticals | Small Cap Growth
Based in Ireland
Company profile

Nabriva Therapeutics plc is a biopharmaceutical company engaged in the commercialization and development of anti-infective agents to treat serious infections. The Company’s product XENLETA (lefamulin), is a semi-synthetic pleuromutilin antibiotic for systematic administration in humans. It inhibits the synthesis of bacterial protein, which is required for bacteria to grow by binding with high affinity, high specificity and at molecular targets that are different than other antibiotic classes. The Company is also developing CONTEPO (fosfomycin) for injection, a potential first-in-class epoxide antibiotic for complicated urinary tract infections (cUTI), including acute pyelonephritis.

Day's Change
-0.0337 (-5.10%)
B/A Size
Day's High
Day's Low
(Heavy Day)

Today's volume of 1,940,923 shares is on pace to be much greater than NBRV's 10-day average volume of 2,903,555 shares.


Global Market for Antiviral Drugs: Recent Developments by Key Market Participants Including Gilead Sciences, AbbVie and Cipla Inc. -

4:51 am ET May 11, 2020 (BusinessWire) Print

The "Antiviral Drugs Market Size, Share & Trends Analysis Report by Drug Class, by Application (HIV, Hepatitis, Influenza), by Type (Branded, Generic), by Region, and Segment Forecasts, 2020 - 2027" report has been added to's offering.

The global antiviral drugs market size is expected to reach USD 46.9 billion by 2027. It is estimated to register a CAGR of -2.3% over the forecast period. An increasing geriatric population is considered to be the major factor anticipated to drive the demand for efficient treatment of human immunodeficiency virus (HIV) infections.

According to the Centers of Disease Control and Prevention (CDC), nearly half the people diagnosed with HIV in U.S. are aged 50 and older. The number of persons aged 80 years and above is estimated to triple, from 143 million in 2019 to 426 million in 2050. The increasing aging population worldwide will have a direct impact on the healthcare systems, who would have to meet the needs of the aging population. This, in turn, will drive the demand for antiviral drugs, which can be used to treat a range of viral infections.

The presence of pipeline antiviral products for HIV therapeutics is anticipated to drive the market over the forecast period. For instance, ViiV Healthcare is developing Cabotegravir/rilpivirine (long-acting injectable), which is currently under Phase III and are types of NNRTI/ INSTI drug class. In addition, GS-6207 (capsid inhibitor) and vesatolimod (TLR-7 agonist) are being developed by Gilead Sciences and are currently under Phase I trial for the treatment of HIV. Moreover, advancements in epidemiology and growing awareness of viral diseases are expected to result in a high demand for efficient treatment solutions.

Further key findings from the report suggest:

Reverse transcriptase inhibitors held the largest share in 2019 and is estimated to be the fastest-growing segment over the forecast period as these inhibitors slow down or prevent viral replication DNA polymerase inhibitors was the second-largest segment in 2019 owing to its effectiveness in combating drug resistance Generic products are estimated to be the fastest-growing segment over the forecast period owing to increased adoption of generic drugs in developing countries Hepatitis dominated the application segment in 2019 owing to the availability of various antiviral products for its treatment HIV is estimated to be the fastest-growing segment over the forecast period due to its increasing prevalence and incidence rate North America dominated the global antiviral drugs market in 2019 owing to the presence of key players in the region and the availability of a well-established healthcare infrastructure.

Key Topics Covered:

Chapter 1. Methodology and Scope

Chapter 2. Executive Summary

Chapter 3. Antiviral Drugs Market Variables, Trends & Scope

3.1. Market Lineage outlook

3.2. Penetration & Growth Prospect Mapping

3.3. Pipeline Analysis

3.4. Market Dynamics

3.5. Antiviral Drugs: Market Analysis Tools

Chapter 4. Antiviral Drugs Market: Segment Analysis, By Drug Class, 2016 - 2027 (USD Billion)

4.1. Definitions & Scope

4.2. Drug class market share analysis, 2019 & 2027

4.3. Segment Dashboard

4.4. Global Antiviral Drugs Market, By Drugs Class, 2016 to 2027

4.5. Market Size & Forecasts and Trend Analyses, 2016 to 2027 for the following

Chapter 5. Antiviral Drugs Market: Segment Analysis, By Type, 2016 - 2027 (USD Billion)

5.1. Definitions & Scope

5.2. Type market share analysis, 2019 & 2027

5.3. Segment Dashboard

5.4. Global Antiviral Drugs Market, By Type, 2016 to 2027

5.5. Market Size & Forecasts and Trend Analyses, 2016 to 2027 for the following

Chapter 6. Antiviral Drugs Market: Segment Analysis, By Application, 2016 - 2027 (USD Billion)

6.1. Definitions & Scope

6.2. Application market share analysis, 2019 & 2027

6.3. Segment Dashboard

6.4. Global Antiviral Drugs Market, By Application, 2016 to 2027

6.5. Market Size & Forecasts and Trend Analyses, 2016 to 2027 for the following

Chapter 7. Antiviral Drugs Market: Regional Market Analysis, By Region, 2016 - 2027 (USD Billion)

7.1. Definitions & Scope

7.2. Regional market share analysis, 2019 & 2027

7.3. Regional Market Dashboard

7.4. Regional Market Share and Leading Players, 2019

7.5. SWOT Analysis, by Factor (Political & Legal, Economic And Technological)

7.6. Market Size, & Forecasts and Trend Analysis, 2019 to 2027

Chapter 8. Antiviral drugs market - Competitive Analysis

8.1. Recent developments & impact analysis, by key market participants

8.2. Company/Competition Categorization (Key innovators, Market leaders, Emerging players)

8.3. Public Companies

8.4. Private Companies

8.5. Key companies profiled

Gilead Sciences F. Hoffmann-La Roche AG GlaxoSmithKline plc. AbbVie Merck & Co., Inc. Johnson & Johnson Services, Inc. Bristol-Myers Squibb Company Cipla Inc. Aurobindo Pharma Dr. Reddy's Laboratories Ltd.

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

View source version on

SOURCE: Research and Markets
Laura Wood, Senior Press Manager 

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.